Diagnostics News and Research

RSS

Medwell acquires ownership and control over 6,449,501 common shares of Spectral

Spectral Diagnostics Inc., a Phase III company developing the first theranostic treatment for severe sepsis and septic shock, and Medwell Capital Corp., today jointly announced a non-brokered agreement whereby Medwell and a consortium of buyers purchased in private transactions 12,449,501 common shares and 962,500 common share purchase warrants of Spectral from GrowthWorks Canadian Fund Ltd., representing 15.6% of the issued and outstanding shares.

28 Mar 2011

GE launches new specialty musculoskeletal MR scanner

GE today announced the launch of the Optima MR430s, a new specialty scanner with breakthrough technology that delivers precise imaging with exceptional comfort and the 1.5T image quality radiologists require.

28 Mar 2011

ALCMI launches new CASTLE study to treat lung cancer

The Addario Lung Cancer Medical Institute today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States.

28 Mar 2011

Gates discusses foundation's global health priorities in India during visit to country

During a visit to the Indian state of Bihar, Bill Gates, co-founder of the Bill & Melinda Gates Foundation, on Thursday discussed his foundation's work in India and global health priorities, ANI/Sify News reports.

28 Mar 2011

NeoProteomics secures exclusive option agreement with Case Western Reserve University

NeoProteomics Inc., a biomarker development and software company, has secured an exclusive option agreement with Case Western Reserve University. The deal has potential to enhance various forms of treatment of cancer, diabetes, and inflammatory diseases.

28 Mar 2011

Biognosys brings proteomic breakthroughs to mainstream users

Biognosys, a leading provider of targeted proteomics solutions, announces the software platform mProphet for large-scale applications in industrial and academic research. The software was recently published in «Nature Methods»: With the new tool researchers can analyze complex proteomics data and generate statistically validated results.

From Biognosys 25 Mar 2011

Study develops new approaches for sorting out complexities of cancer cells

New drugs that specifically target the mutated genes responsible for cancer growth have shown great success in extending the lives of patients, with far fewer side effects than conventional anti-cancer therapies. Unfortunately, many patients become resistant to these drugs due to secondary mutations.

25 Mar 2011

Financial Times, other media outlets highlight key issues in Global TB fight

In recognition of World Tuberculosis Day on Thursday, the Financial Times published a series of stories on TB worldwide.

25 Mar 2011

Althea extends labeling, packaging of biological product services through Sherpa

Althea Technologies, Inc. announced today that it has extended its service offering to include labeling, packaging, storage and distribution of drug and biological products through its co-marketing partner, Sherpa Clinical Packaging.

25 Mar 2011

SeraCare launches new HIV panel

SeraCare Life Sciences, a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announces the launch of its new Worldwide HIV Performance Panel.

25 Mar 2011

Opinions: Using taxes to reduce poverty; fighting TB; meeting global food demands

To improve living standards and create jobs," African governments "need to provide their citizens with better health care, better education, more infrastructure. How to pay for this - in a way that is both fair and efficient - is a question that all governments face," Mark Plant, deputy director of the IMF's African Department, writes in a BusinessDay opinion piece where he describes how increased tax revenues in several African countries have led to "in-roads into poverty reduction."

25 Mar 2011

FDA approves Medtronic's Consulta and Syncra pacemaker systems

Medtronic, Inc. today announced that the U.S. Food & Drug Administration has approved its Consulta and Syncra cardiac resynchronization therapy-pacemaker systems.

25 Mar 2011

HDL, BG Medicine to offer galectin-3 testing services for patients with heart failure

Health Diagnostic Laboratory, Inc. and BG Medicine, Inc., announced today an agreement under which HDL, Inc. will offer galectin-3 testing services based on the BG Medicine Galectin-3 Test.

25 Mar 2011

Imaging with voltage-sensitive dye captures real-time brain dynamics

The dye incorporates in the brain cells' membrane and changes fluorescence whenever these receive or send electrical signals. Hence, high resolution camera systems allow to simultaneously capture activities of millions of nerve cells across several square millimeters across the brain.

24 Mar 2011

New insights into multiple myeloma research

Scientists have unveiled the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, a form of blood cancer. A study of the genomes from 38 cancer samples has yielded new and unexpected insights into the events that lead to this form of cancer and could influence the direction of multiple myeloma research.

24 Mar 2011

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics.

24 Mar 2011

Contrast agent for tumor diagnostics

X-rays are not the only way: visible and especially infrared light can also be used to image human tissue. The effectiveness of optical imaging processes can be significantly improved with suitable dyes used as contrast agents. In the journal Angewandte Chemie, a team led by Wenbin Lin at the University of North Carolina (Chapel Hill, USA) has now introduced a novel contrast agent that marks tumor cells in vitro. The dye is a phosphorescent ruthenium complex incorporated into nanoparticles of a metal–organic coordination polymer, which allows an extraordinarily high level of dye loading.

23 Mar 2011

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

Asuragen, Inc. announced that they have achieved CE-marking and commercial launch in Europe of the AmplideX FMR1 PCR Kit for the detection of CGG repeats in the fragile X mental retardation gene.

23 Mar 2011

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.

21 Mar 2011

Quest Diagnostics proposes $1,250,000,000 senior notes offering

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $1,250,000,000 in aggregate principal amount of four series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.

From Quest Diagnostics 21 Mar 2011